Quantum Cyber N.V. QUCY
tests for the early detection of cancer. In March 2025, we acquired a license from Liquid Bioscience, Inc. to access a portfolio of novel
mRNA biomarkers and AI developed proprietary algorithm, for the non-invasive detection of pancreatic cancer with a blood test. We have
an exclusive license to develop such a test using these biomarkers and algorithm with the unilateral option to acquire them. We are also
developing a product candidate called PancAlert, a stool-based screening test aimed at detecting pancreatic cancer. We have received non-refundable
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $537.1K | $894.0K | $895.5K | $529.9K | $577.3K | $493.6K | $281.4K | — |
| Cost of revenue | $147.3K | $319.1K | — | — | — | — | — | — |
| Gross profit | $389.8K | $574.9K | — | — | — | — | — | — |
| R&D | $4.9M | $5.7M | — | — | — | — | — | — |
| SG&A | $5.1M | $6.7M | — | — | — | — | — | — |
| Total operating expenses | $16.5M | $19.3M | — | — | — | — | — | — |
| Operating income | -$16.1M | -$18.8M | -$26.6M | -$26.4M | -$9.7M | -$673.7K | -$921.9K | — |
| Interest expense | $373.5K | $945.5K | — | — | — | — | — | — |
| Pre-tax income | -$16.2M | -$21.6M | — | — | — | — | — | — |
| Net income | -$16.2M | -$21.6M | -$26.3M | -$26.4M | -$11.7M | -$586.9K | -$957.1K | — |
| EPS, basic | -2.70 | -21.91 | — | — | — | — | — | — |
| EPS, diluted | -2.70 | -21.91 | — | — | — | — | — | — |
| Shares, diluted (wtd. avg.) | $6.0M | $985.7K | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $889.1K | $6.2M | $7.1M | — | — | — | — | — |
| Inventory | $216.9K | $372.9K | — | — | — | — | — | — |
| Total current assets | $1.8M | $8.0M | — | — | — | — | — | — |
| Property, plant and equipment | $1.1M | $1.4M | — | — | — | — | — | — |
| Other intangibles | $1.1M | $3.0M | — | — | — | — | — | — |
| Total assets | $5.3M | $13.5M | $15.4M | $20.2M | $10.0M | $673.3K | — | — |
| Accounts payable | $411.1K | $1.3M | — | — | — | — | — | — |
| Short-term debt | $956.9K | $1.0M | — | — | — | — | — | — |
| Total current liabilities | $3.7M | $6.2M | — | — | — | — | — | — |
| Total liabilities | $4.7M | $7.5M | — | — | — | — | — | — |
| Retained earnings | -$104.9M | -$88.7M | — | — | — | — | — | — |
| Total equity | $641.6K | $6.0M | $3.4M | $14.1M | $6.4M | -$2.7M | -$2.0M | -$1.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.0M | -$17.3M | — | — | — | — | — | — |
| Depreciation and amortisation | $615.7K | $696.6K | — | — | — | — | — | — |
| Stock-based compensation | $1.5M | -$63.1K | — | — | — | — | — | — |
| Capital expenditure | $1.2K | $104.9K | — | — | — | — | — | — |
| Investing cash flow | -$1.0M | -$198.8K | — | — | — | — | — | — |
| Financing cash flow | $6.8M | $16.8M | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-037676.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |